Pandemic Antiviral Discovery | Antivirals for Pandemic Influenza RFP

Thumbnail

Event details

Date 14.12.2022  
Category Conferences - Seminars
UPDATE: New deadline of 14 December 2022 (updated from 22.11.22)

Aim:
 This RFP will support research designed to develop novel small-molecule antivirals targeting pandemic influenza. PAD funding can support preclinical activities and phase I clinical trials, but not later stage clinical trials. Special consideration will be given to therapeutic modalities that are suitable for deployment in low resource settings. Researchers from around the world are encouraged to submit proposals.

Proposals should be consistent with at least one of these 4 areas:
  • Direct acting antivirals with data demonstrating clear differentiation from currently marketed influenza antiviral products
  • Host targeted therapies with data demonstrating clear benefit over currently marketed influenza virus therapeutics
  • Compounds that target multiple pathways or mechanisms to reduce the likelihood of resistance emergence
  • Compounds demonstrating activity against drug resistant influenza variants
In addition to improved clinical efficacy over standard of care, attributes that define differentiation include shorter duration of therapy, reduced dosing frequency, improved safety, lower cost of goods, higher barrier to resistance and/or novel targets/mechanism of action.

Funding:       $2M (exploratory projects)
                       $10M (validation projects)

Duration:      1 – 3 years

Eligibility: Applicants must be established investigators with their own line of research and must be employed for the duration of the project at the administrating institution registered in the proposal. Projects can be anchored at any type of research organization, including academia, not-for profit and commercial organizations. The scope of the project must be within the scientific scope of this RfP and support the PAD aspirations. An applicant (i.e., the principal investigator (PI) responsible for the project and submitting the proposal) may submit only one proposal to this specific RfP.

How to Apply: The 2-step application process begins with a pre-proposal, which can be submitted via the NORMA platform.  Proposals and material submitted will be evaluated by scientific program officers from Bill and Melinda Gates Foundation, Open Philanthropy and Novo Nordisk Foundation. Based on this evaluation, the outcome can be either an invitation to submit a full proposal to one of the three foundations or a rejection letter informing the applicants that their proposal will not be considered for funding. Notification of outcome of the first phase is expected by the end of May 2023. Upon invitation to submit a full proposal to one of the three foundations, applicants will work directly with that specific foundation to develop the full application, and the processes may differ depending on the foundation.

Deadline:      14-December-2022

Further information
  • More information about the program is available here
  • The application portal can be found here
  • For any other questions, please contact the Research Office

Practical information

  • General public
  • Free

Contact

Event broadcasted in

Share